Compound blood pressure reducing prepn containing angiotonin converzyme inhibitor, calcium ion agonist and Estazolam
A technology of converting enzyme inhibitors and calcium ion antagonists, applied in the field of compound antihypertensive preparations, can solve problems such as unsatisfactory and side effects reduction
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1-7
[0053] Preparation of compound antihypertensive preparation
[0054] The enalapril used is enalapril maleate tablets, produced by Yangzijiang Pharmaceutical; Production. The calcium ion antagonist nifedipine is nifedipine, produced by Changzhou Pharmaceutical Factory; amlodipine is Norvasc, produced by Pfizer Pharmaceuticals; and nitrendipine is produced by Nantong No. 3 Pharmaceutical Factory. Estazolam is produced by Beijing Yimin Pharmaceutical.
[0055] The formulations in Table 1 are prepared into capsules according to the conventional method in the pharmaceutical industry, and there are 21 kinds in total.
[0056] Example
Embodiment 8
[0058] Combined administration of angiotensin-converting enzyme inhibitors, calcium antagonists and estazolam
[0059] The present invention uses prospective, control group, single-blind, multi-center clinical trials to randomly divide 160 hypertensive patients into Nazepril group, Nifedipine group, Enalapril combined with Nifedipine compound preparation group, and Napril combined with nifedipine and estazolam compound preparation group was observed and treated for an average of 6 months.
[0060] Table 2 enalapril group, nifedipine group, enalapril combined with nifedipine compound preparation group, and
[0061] group
average dose
mg
Mean blood pressure mmHg
treatment result
Before treatment
Average Buck
Amplitude%
Compliance rate
%
Efficient
%
1 enalapril
Group n = 39
15.4±8.2
159.7±17.7 /
91.1±7.6
141.2±16.8 /
84.6±6.8
11.6...
Embodiment 9
[0084] Combined administration of angiotensin-converting enzyme inhibitors, calcium antagonists and estazolam
[0085] In the present invention, prospectively, with a control group, single-blind, 122 patients with essential hypertension were randomly divided into ramipril group, amlodipine group, ramipril combined with amlodipine compound preparation group, and ramipril group. The Puli combined with amlodipine and estazolam compound preparation group was observed and treated for an average of 8 weeks.
[0086] Table 4 ramipril group, amlodipine group, ramipril combined with amlodipine compound preparation group, and
[0087] group
average dose
mg
Mean blood pressure mmHg
treatment result
Before treatment
Average Buck
Amplitude%
Compliance rate
%
Efficient
%
1 ramipril
Group n = 30
10.8±7.4
157.8±16.9 / 9
0.5±6.8
140.7±15.7
/
85.1±5.9
...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com